Checkpoint Therapeutics, Inc. (CKPT): Price and Financial Metrics
GET POWR RATINGS... FREE!
CKPT POWR Grades
- Sentiment is the dimension where CKPT ranks best; there it ranks ahead of 57.82% of US stocks.
- The strongest trend for CKPT is in Stability, which has been heading down over the past 179 days.
- CKPT ranks lowest in Momentum; there it ranks in the 4th percentile.
CKPT Stock Summary
- For CKPT, its debt to operating expenses ratio is greater than that reported by merely 0.5% of US equities we're observing.
- With a price/sales ratio of 618.58, Checkpoint Therapeutics Inc has a higher such ratio than 99.27% of stocks in our set.
- As for revenue growth, note that CKPT's revenue has grown -74.93% over the past 12 months; that beats the revenue growth of only 1.68% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Checkpoint Therapeutics Inc are ARDS, AUTL, ZYME, PIRS, and NVAX.
- Visit CKPT's SEC page to see the company's official filings. To visit the company's web site, go to www.checkpointtx.com.
CKPT Valuation Summary
- In comparison to the median Healthcare stock, CKPT's price/sales ratio is 25118.42% higher, now standing at 958.3.
- CKPT's price/sales ratio has moved up 860.2 over the prior 51 months.
- CKPT's price/sales ratio has moved up 860.2 over the prior 51 months.
Below are key valuation metrics over time for CKPT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| CKPT | 2021-08-31 | 958.3 | 4.7 | -8.6 | -6.5 |
| CKPT | 2021-08-30 | 940.6 | 4.6 | -8.5 | -6.4 |
| CKPT | 2021-08-27 | 901.8 | 4.4 | -8.1 | -6.0 |
| CKPT | 2021-08-26 | 880.9 | 4.3 | -8.0 | -5.8 |
| CKPT | 2021-08-25 | 883.8 | 4.3 | -8.0 | -5.9 |
| CKPT | 2021-08-24 | 857.2 | 4.2 | -7.7 | -5.6 |
CKPT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- CKPT has a Quality Grade of D, ranking ahead of 20.58% of graded US stocks.
- CKPT's asset turnover comes in at 0.005 -- ranking 410th of 682 Pharmaceutical Products stocks.
- VBIV, COLL, and ARWR are the stocks whose asset turnover ratios are most correlated with CKPT.
The table below shows CKPT's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.005 | 1 | 4.869 |
| 2021-03-31 | 0.004 | 1 | 4.383 |
| 2020-12-31 | 0.033 | 1 | 3.944 |
| 2020-09-30 | 0.037 | 1 | 3.435 |
| 2020-06-30 | 0.061 | 1 | 3.348 |
| 2020-03-31 | 0.117 | 1 | 3.498 |
CKPT Price Target
For more insight on analysts targets of CKPT, see our CKPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $15.80 | Average Broker Recommendation | 1.4 (Strong Buy) |
CKPT Stock Price Chart Interactive Chart >
CKPT Price/Volume Stats
| Current price | $1.05 | 52-week high | $4.64 |
| Prev. close | $1.03 | 52-week low | $0.96 |
| Day low | $1.01 | Volume | 212,600 |
| Day high | $1.08 | Avg. volume | 1,070,198 |
| 50-day MA | $1.24 | Dividend yield | N/A |
| 200-day MA | $2.32 | Market Cap | 95.58M |
Checkpoint Therapeutics, Inc. (CKPT) Company Bio
Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Latest CKPT News From Around the Web
Below are the latest news stories about Checkpoint Therapeutics Inc that investors may wish to consider to help them evaluate CKPT as an investment opportunity.
Checkpoint Therapeutics Inc. (NASDAQ:CKPT) Stock Plunged -23.15% So Far In 2022, What Analysts Expect Next?In last trading session, Checkpoint Therapeutics Inc. (NASDAQ:CKPT) saw 0.87 million shares changing hands with its beta currently measuring 1.69. Companys recent per share price level of $2.39 trading at $0.0 or 0.00% at ring of the bell on the day assigns it a market valuation of $185.56M. That closing price of CKPTs stock is Checkpoint Therapeutics Inc. (NASDAQ:CKPT) Stock Plunged -23.15% So Far In 2022, What Analysts Expect Next? Read More » |
2 Biotech Stocks That Could Be 10-Baggers in 2022These two clinical-stage biotechs have major upcoming catalysts that could catapult their shares higher. |
Checkpoint Therapeutics'' Cosibelimab Posts 47.4% ORR In Skin Cancer PatientsCheckpoint Therapeutics Inc (NASDAQ: CKPT ) announced topline results from its registration-enabling clinical trial evaluating cosibelimab, administered as a fixed dose of 800 mg every two weeks in patients with metastatic cutaneous squamous cell carcinoma (cSCC). The study met its primary endpoint, with cosibelimab demonstrating a confirmed objective response rate (ORR) of 47.4%. The median duration of response (DOR) had Full story available on Benzinga.com |
Checkpoint reports positive results from registration trial of cosibelimab in skin cancerCheckpoint Therapeutics (CKPT) announces positive topline results from its registration-enabling clinical trial evaluating the safety and efficacy of its anti-PD-L1 antibody, |
Checkpoint Therapeutics to Participate in the B. Riley Securities’ Virtual Oncology ConferenceWALTHAM, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat hosted by Justin Walsh, Equity Research Analyst (Biotechnology), at the B. Riley Securities’ Virtual Oncology Conference, taking place on Thursday, January 27, 2022, at 11:00 a.m. EST. Checkpoint management will als |
CKPT Price Returns
| 1-mo | -27.59% |
| 3-mo | -40.68% |
| 6-mo | -66.24% |
| 1-year | -65.46% |
| 3-year | -68.75% |
| 5-year | -89.23% |
| YTD | -66.24% |
| 2021 | 17.36% |
| 2020 | 54.07% |
| 2019 | -5.49% |
| 2018 | -53.09% |
| 2017 | N/A |
Continue Researching CKPT
Here are a few links from around the web to help you further your research on Checkpoint Therapeutics Inc's stock as an investment opportunity:Checkpoint Therapeutics Inc (CKPT) Stock Price | Nasdaq
Checkpoint Therapeutics Inc (CKPT) Stock Quote, History and News - Yahoo Finance
Checkpoint Therapeutics Inc (CKPT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...